A Phase 1b Study of Neoadjuvant Xaluritamig in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511965-13-00

Acronym

20230237

Enrollment

Registered

2024-10-18

Start date

2024-11-25

Completion date

Unknown

Last updated

2025-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly diagnosed localized Intermediate or High‐Risk Prostate Cancer

None listed

Sex/Gender

Male

Age

18 Years to 64 Years

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026